PHILLIPSBURG, NJ — The Sher Institute for Reproductive Medicine(SM)-New Jersey, part of one of the largest and fastest growing infertility networks in the United States, announces the opening of Sher Institute for Reproductive Medicine(TM) – Greater Lehigh Valley (SIRM(TM)-GLHV) in partnership with Dr. Albert Peters.
Dr. Peters, who has served as Chief of the Division of Reproductive Endocrinology and Infertility at Lehigh Valley Hospital for the past 10 years will assume the role of Medical Director of SIRM(TM)-GLHV. Dr. Peters is a board certified Reproductive Endocrinologist that has treated thousands of infertile couples with an outstanding record of success. Dr. Peters’ main clinical interests lie in the area of general infertility, recurrent miscarriage and menopause. He has a unique approach to these clinical problems by incorporating into traditional reproductive health methodologies various eastern philosophies such as acupuncture, message, yoga, tai chi and herbology.
Located in Phillipsburg, New Jersey, SIRM(TM)-GLHV, will have exclusive access in the Greater Lehigh Valley to various SIRM(TM) breakthrough technologies in the field of In Vitro Fertilization (IVF) that have the potential to dramatically increase the odds of a woman getting pregnant through IVF, while at the same time reducing the likelihood of multiple births.
“I’m extremely excited to lead the Sher Institutes’ office here and bring their outstanding tradition of compassionate care and cutting-edge technology to the area,” said Dr. Peters. “I’m confident that the people of the valley will find SIRM a great resource.”
One recent example of this proprietary technology is the subject of several studies by SIRM(TM) Founder Geoffrey Sher, M.D. and Levent Keskintepe Ph.D. of ReproCureTM, LLC. The studies demonstrate that a new process for the testing of early embryos may help determine which ones are most likely to produce normal pregnancies in IVF patients. This could lead to a major improvement in IVF success rates for practices using this testing method. The current national average pregnancy rate is 30% per treatment cycle in women under 40. Furthermore, the researchers report that these increases can be achieved by transferring no more than one (1) or sometimes two (2) embryos, thereby virtually eliminating the risk of high order multiple births (triplets or greater).
This testing process focuses on the measurement of a genetic marker called Human Leukocyte Antigen-G (HLA-G) released by the 2-day-old embryo in the media in which it is developing.
This research was published in the medical journal Fertility and Sterility as well as the medical journal Human Reproduction and will be presented at an international conference in Europe later this year.
Another process for testing the DNA of an egg prior to fertilization is nearing the final stage of investigation and promises to be even more predictive of egg/embryo “competence.” The researchers, working in collaboration with a team of Japanese scientists have applied this method to improve the ability to successfully freeze human eggs without causing a large reduction in the thawed egg’s ability to subsequently fertilize and produce embryos.
“Previous methods for selecting the best quality embryos for transfer to the uterus relied mainly on visual assessment of individual embryos by microscope,” said Dr. Sher. “Those types of evaluations are severely limited in their ability to provide any strong indication of subsequent normal embryonic and fetal development.”
Because of the limitations of current embryo assessment methods, there has been a tendency among many IVF practitioners to transfer more, rather than fewer embryos to the patient’s uterus in the hope of improving the chances of pregnancy. This in turn has led to a high rate of high-order multiple pregnancies (triplets or more) with inherent long-term or even life-endangering risks to both mother and children. “The explosion in the rate of higher order pregnancies as a result of IVF has created an enormous burden on the health care system,” explains Dr. Sher. “This is the primary reason why most insurance companies don’t currently cover IVF.”
“The advantage of this new methodology is twofold,” states Dr. Peters. “First, it dramatically increases the chances of success with IVF. Second, by allowing us to select the best embryos to transfer, we can reduce the total number of embryos transferred and thereby reduce the incidence of triplet pregnancies or greater.”
About SIRM(TM)
The Sher Institutes for Reproductive Medicine(TM) (SIRM(TM)) are a network of independently owned IVF centers and satellite offices that operate under a shared set of practice standards and centralized management systems. SIRM(TM) founder, Dr. Geoffrey Sher, established the country’s first private IVF practice in 1982. SIRM(TM) physicians have been influential in the development of numerous breakthroughs in the field of reproductive care over the past 23 years.
SIRM(TM) offices are located in Long Island, Manhattan, and Westchester, New York; Bedminster and Monmouth County, New Jersey; St. Louis, Missouri; Los Angeles, Orange County, Chino Hills, West Hills, Sacramento and Pleasanton, California; Dallas, Texas; Las Vegas, Nevada, and Peoria, Illinois. Further information about the Sher Institutes for Reproductive Medicine can be found on the SIRM(TM) website at www.haveababy.com.
NEWS SOURCE: Sher Institute for Reproductive Medicine – New Jersey
[tags]SIRM, IVF, in vitro fertilization, parenting, pregnancy, Sher Institutes for Reproductive Medicine, Dr. Sher, Human Leukocyte Antigen-G, Fertility and Sterility, New Jersey[/tags]
